Genomic Health Inc. (GHDX)
-NasdaqGS 30.56 
0.23(0.76%) 4:00PM EDT|After Hours
:
30.56 0.00 (0.00%) 5:34PM EDT
| Prev Close: | 30.33 |
|---|
| Open: | 30.12 |
|---|
| Bid: | N/A |
|---|
| Ask: | 37.80 x 800 |
|---|
| 1y Target Est: | 35.69 |
|---|
| Beta: | 0.73 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 30.00 - 30.67 |
|---|
| 52wk Range: | 25.25 - 38.99 |
|---|
| Volume: | 213,631 |
|---|
| Avg Vol (3m): | 110,962 |
|---|
| Market Cap: | 935.81M |
|---|
| P/E (ttm): | 517.97 |
|---|
| EPS (ttm): | 0.06 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Genomic Health presents Oncotype DX studies reinforcing value of teststheflyonthewall.com(Tue, Oct 1)
- InPlay: Genomic Health presents Oncotype DX studies reinforcing value of tests in guiding treatment for multiple cancersBriefing.com(Tue, Oct 1)
- Genomic Health Announces Presentation of Oncotype DX® Studies Reinforcing Value of Tests in Guiding Treatment for Multiple CancersPR Newswire(Tue, Oct 1)
- Medicare's Greatest Enemy Won't Be Defundedat Motley Fool(Thu, Sep 26)
- NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer PatientsPR Newswire(Wed, Sep 25)
- GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Sep 20)
- Genomic Health: Market Leader In Cancer Predictionsat Seeking Alpha(Tue, Aug 27)
- Is Myriad Innovative Enough To Survive The Competition?at Seeking Alpha(Fri, Aug 23)
- Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to Predict Chemotherapy BenefitPR Newswire(Thu, Aug 22)
- Interview with William Quirk, Piper Jaffray & Co. Managing Director and Senior Research Analyst: Solid Fundamentals for Diagnostics and Life Science Tools Despite Short-Term ChallengesWall Street Transcript(Wed, Aug 21)
- Richard King, the Director, President and CEO of AcelRx Pharmaceuticals, Inc. (ACRX), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Aug 16)
- GENOMIC HEALTH INC FinancialsEDGAR Online Financials(Thu, Aug 15)
- Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth ConferencePR Newswire(Wed, Aug 7)
- GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Aug 7)
- Did Emeritus and These Stocks Miss or Beat Analyst Expectations?at Wall St. Cheat Sheet(Sun, Aug 4)
Key Statistics
| Forward P/E (1 yr): | 132.87 |
|---|
| P/S (ttm): | 3.78 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.12 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.03 |
|---|
| Mean Recommendation*: | 2.8 |
|---|
| PEG Ratio (5 yr expected): | -14.12 |
|---|
Business Summary
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer,...
View More